Apr 01, 2026 | FDA Approves Lilly's Foundayo Oral Obesity Pill; Immunovant Batoclimab Fails Phase 3 TED Trials

Lilly's Foundayo becomes the first oral GLP-1 approved forobesity in the U.S. — LLY jumps 3.78%. Immunovant's batoclimab misses both Phase 3 endpoints in thyroid eye disease. Plus: Merck-Infinimmune $838M antibody deal, Blackstone's record $6.3B life sciences fund, and the WhiteHouse readies 100% tariffs on imported brand-name drugs.www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Foundayo, orforglipron, Eli Lilly, obesity, GLP-1, oral obesity pill, FDA approval, Immunovant, batoclimab, thyroid eye disease, FcRn, Merck, Infinimmune, Blackstone, Cogent Biosciences, bezuclastinib, GIST, Cyclerion, Korsana, Novo Nordisk, Wegovy, PADCEV, KEYTRUDA, drug tariffs, Lilly, Roche, AstraZeneca, Sanofi, Amgen, Gilead, Vertex